ArticleAnnals of medicine2025
Global burden, trends and inequalities of hepatitis B among women of childbearing age, 1990-2021.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of Hepatitis B Virus Infection in Cameroon: A Systematic Review and Meta-Analysis.Journal of viral hepatitis · 2026Pooled it
- Hepatoprotective effects of modified Yiguanjian decoction in pregnant patients with chronic hepatitis B.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWomen of childbearing age (WCBA) are a key group for hepatitis B virus (HBV) infection elimination and maternal health. We aimed to investigate global patterns, trends and inequalities in the burden of HBV among WCBA based on the Global Burden of Disease 2021 database.
methodsWe extracted data on the prevalence of chronic HBV infection and HBV-related mortality among WCBA in 204 countries and territories from 1990 to 2021. The estimated annual percentage change (EAPC) was calculated to quantify the temporal trends in age-standardized prevalence (ASPR) and mortality rate (ASMR). Inequalities across countries in chronic HBV infection and HBV-related deaths were measured using the concentration index.
resultsIn 2021, the global ASPR per 100,000 population of chronic HBV infection among WCBA was 3664, corresponding to 71.4 million infected people. From 1990 to 2021, the global ASPR declined annually by 1.2%, while prevalence rates remained relatively high in Central and Western Africa. HBV-related ASMR declined worldwide (EAPC = -1.49%, 95% CI: -1.55, -1.42), whereas upward trends were observed in the United Kingdom (EAPC = 1.79, 95% CI: 1.41, 2.18) and Poland (EAPC = 1.29, 95% CI: 0.89, 1.69). Both the number of chronic HBV infection cases and HBV-related deaths in low socio-demographic index (SDI) region showed an increasing trend. SDI-related inequality in chronic HBV infection increased from 1990 to 2021, except in high-income countries, Latin America and the Caribbean.
conclusionsThe global prevalence of chronic HBV infection among WCBA declined over time, but low SDI countries remained a region of concern. Furthermore, the concentration of HBV disease burden among disadvantaged populations requires targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.